SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 27, 2016) - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform, today announced that it has been added to the broad U.S. market Russell® 3000 Index and the small-cap Russell 2000® Index as part of Russell Investments' annual reconstitution of its stock indexes, effective at the opening of U.S. markets today.
"We are very pleased to be added to the Russell 3000 and 2000 indexes and we look forward to the broader exposure and potential interest in the company among new institutional investors that inclusion provides," Titan CEO and President Sunil Bhonsle said. "Titan's inclusion in the Russell indexes comes on the heels of the recent approval by the U.S. Food and Drug Administration of Probuphine for the maintenance treatment of opioid addiction, and we hope to continue this momentum through the planned development of additional products based on our ProNeura long-term, continuous drug delivery platform."
I posted this before here, but my barber is a young man who struggled with addiction. He is sober now and functioning well, it seems, but used suboxone to help him through the process. He is a musician and knows many who struggle with addiction, rehab and the "trigger" mechanism. In the past, we've talked about Probuphine and he said that he couldn't imagine people not wanting to, at least, try it. He thought it was a wonderful approach and should be successful, if it works well. GLTA !!
You are the type that always seems to have the last word, so this will be my last post to you.
Regards PE, I said (respectfully) with no intention to even begin to insult you. My point here was that my view of TTNP's potential value with regard to the application of a PE would be based on earnings, which have to be based on sales. That has always been my premise and my only premise. I may have missed it, but you claimed that TTNP is undervalued but never really said why. My position, lame as it may be to you and others, is to simply posit my premise as to why it's not undervalued right now, but is in a dead period, as interested observers await to see if Probuphine sells. OT: I am very familiar with DNDN, SVNT, NAVB and ARNA because I lost quite a bit of money on them, simply because they ran up in anticipation of sales that never happened. DNDN and SVNT did so, especially, based on analysts projections and Management's guidance. I think many in biotech have learned from this lesson, especially DNDN.
After having this exchange and repartee with you, I now have a better understanding of why you chose your particular id ..... :-) GOOD LUCK with TTNP.
look baffle......we're not arguing, whether it's incongruous, or not. You think TTNP is currently undervalued and feel it's not comparable to others (at least not to those I've mentioned). You may be right about that. I just feel that projections have to be made by anyone trying come up with a decision to buy, sell or hold. I get your PE point, also, but (respectfully) you have to have earnings to have a PE to being with. What are the projections for TTNP's future earnings? I don't know, but they will start with royalties based on sales of PB. How soon can someone know that those sales will be, with come degree of certainty and confidence? That's all. GLTY and to ALL !!
not really, because PB has been approved. That ship has sailed.....
Royalty Rate us 15%
PB Prescription is $5,000.
TTNP spends $1,000,000 per month
1,333 prescriptions per month are needed for break-even cash flow
What I am waiting for is to see reports that PB prescriptions are nearing 1,000 per month, or quickly headed in that direction with good momentum.
I am free to post and you are free to ignore. It's that simple.
The point I was trying to make is: what happened to the POTENTIAL for the four (4) stocks I mentioned was that, after approval, the products DID NOT SELL and the price plummeted, keeping in mind that TTNP is on a royalty agreement. When the market is convinced that Probuphine will sell, I think the price will begin to rise. This is my opinion and I do not pretend to state this as fact. If there was more demand, more buyers than people looking to sell, I believe the price would be rising. I believe there will be more buyers when they recognize the potential for PB is being realized. Enough said ...... there's not reason to really argue about this, but I simply believe valuations are based on the perceived value of PB sales. That perception is blurred right now. Anyone who is convinced that TTNP is "unfairly" undervalued should be buying shares in confidence. Right now, I cannot do this. GLTY and to ALL !!
lastly, to use your own words, if you "understand the addiction field to predict the future trajectory and uptake of this technology" and are taking the "opportunity to stock up at a discount that the market is gifting"..... and you are right and reap huge rewards, then you are in a select group of astute investors. Congrats. I have already stated that I am not in that group and have decided to wait for some conclusive sales information to decide what to do with TTNP. GLTA !!
If you have owned DNDN, SVNT, NAVB of ARNA, then you might have a better understanding of the dynamic of a biotech firm after getting an approval. If TTNP, right now, is not valued on the marketability of Probuphine, then what is its value based on?
Yes. The constant release of pertinent information is what we need. There will be a tipping point, HOPEFULLY, in the near future (2-3 months) when the market will recognize that PB truly will be a player in the opioid addiction treatment space. GLTA !!
Potential means nothing, if it is not realized. Yes, cash will flow to TTNP. However, TTNP will remain a small research biotech and will expend (burn) cash for R & D activities. The amount of "free" cash is what most are waiting to try and forecast, as this is what will move the stock price, imho. GLTA !!
but it appears obvious to me that the market is waiting for prescription information and a good idea if any sales momentum will be established. This is not unreasonable and I can see the stock drifting down, rather than up, pending no manipulation. The price could represent great buying opportunities for the astute and alert investor. Unfortunately, I do not place myself in that group. GLTA !!
I'm not sure prospector is obsessed, but he seems focused on the hybrid prescribers. I agree with you on your main point. The fully-trained prescribers are certainly convenient and I would imagine to be more inclined to prescribe PB, but I think it's good that there are so many others that are certified to prescribe, even though they may not insert the rods. I clearly see this as more potential for patient coverage, obviously.
I appreciate these kinds of efforts and thank you for them. Perhaps I am misunderstanding your premise, but why do you limit patient count to only those prescribers with insertion/removal training? Won't there be patients prescribed that go to an insertion clinic?